While immunotherapy may be the latest tool in the treatment armamentarium for cancer, many ongoing clinical trials are assessing precision medicine approaches that target specific genetic alterations in patient’s tumors.Read More
The AACR Annual Meeting 2018 drew more than 22,600 people to Chicago, providing a front-row seat to some exciting developments in cancer research. Whether it was the practice-changing results of …Read More
A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …Read More
An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …Read More
This post originally appeared on the Cancer Today website.
“This is a historic time in cancer research,” said Elizabeth Jaffee, president-elect of the American Association for Cancer Research (AACR), citing breakthroughs …
As the 2018 Annual Meeting of the American Association for Cancer Research unfolded yesterday morning, the excitement among the attendees walking through the halls of McCormick Place in Chicago was …Read More
The AACR’s Pediatric Cancer Working Group, which now boasts over 2,500 members, will hold a special scientific session at the Annual Meeting, where ongoing advances and existing challenges in cancer research will be discussed through the pediatric lens.Read More
A study presented in the AACR Annual Meeting 2018 Media Preview webinar, held March 15, examined closely a key ingredient necessary to make effective chimeric antigen receptor (CAR) T cells – the T cells of a patient. The researchers behind this study have identified one potential reason for why we have not been successful in making CAR T-cell therapy work against solid tumors, and offer a solution.Read More
In less than a month, the AACR Annual Meeting 2018 will kick off in Chicago, Illinois. The meeting is expected to draw about 22,000 attendees, including cancer researchers, clinicians, and advocates.
As always, the meeting features a wide range of high-impact science, featuring presentations on all aspects of basic and translational cancer research, including immunotherapy, precision medicine, artificial intelligence, liquid biopsy, early detection, cancer interception, prevention, cancer disparities, and survivorship.Read More
Together with the Radiation Research Society, the AACR will present a workshop titled Targeting Cancer Metabolism to Improve Radiotherapy from February 28 – March 2 in Big Sky, Montana.Read More